Gs. Ungvari et al., Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia, J CL PSYCH, 19(2), 1999, pp. 141-148
Previous antiparkinson drug withdrawal studies involving white subjects hav
e yielded inconclusive findings, whereas there is a paucity of data concern
ing Asian patients. A double-blind, placebo-controlled, randomized trial us
ing gradual withdrawal of antiparkinson medication was conducted to evaluat
e the need for maintenance antiparkinson therapy for clinically stable Chin
ese patients with chronic schizophrenia.
Seventy-five schizophrenic subjects who had received a diagnosis according
to DSM-IV who had been ill for at least 5 years and on antipsychotic and an
tiparkinson medication for a minimum of 2 years entered the study. After ba
seline assessment, 58 subjects were matched according to age, sex, age at o
nset, length of illness, dose and length of antipsychotic and antiparkinson
medication, and the presence of various extrapyramidal side effects. Rando
mly assigned dose-reduction and control groups were formed consisting of 29
subjects each. Trihexyphenidyl (THP), the only oral antiparkinson drug use
d in the study, was reduced by 1 mg every 2 weeks, whereas other psychotrop
ic medication remained unchanged. Monthly assessment was performed using th
e Brief Psychiatric Rating Scale, Hamilton Bating Scale for Depression, Abn
ormal involuntary Movement Scale, Simpson-Angus Scale, Barnes Akathisia Rat
ing Scale, and the Nursing Observation Scale for Inpatient Evaluation-30, C
omplete withdrawal of THP was possible in 25 (90%) of the 28 subjects who c
ompleted the study, whereas considerable dose reduction was achieved in the
remaining 3 subjects. There were no significant differences be-tween dose
reduction and control groups on any of the rating scales at the completion
of the study. Our results suggest that long-term prophylactic administratio
n of antiparkinson medication is unnecessary in the treatment of the majori
ty of Chinese patients with chronic schizophrenia because withdrawal was ac
complished without adverse mental or motor effects.